Condition category
Circulatory System
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Pulmonary embolism (PE) happens when a blood clot, usually from the veins of the legs, breaks off and travels to the lungs. A large clot can cause shortness of breath, chest pain and fainting. In extreme cases, it can cause severe heart and lung damage and even death. Death in pregnancy is very rare, but PE is one of the commonest causes when it happens. The typical symptoms of PE (chest pain or shortness of breath) are common in pregnancy and are not usually cause for alarm. We estimate that only one in every 50 women investigated for suspected PE actually has the condition. Tests for PE are not without risk. Scans used to diagnose the condition use radiation that may slightly increase the risk of cancer in the mother and cause harm to the unborn baby. Furthermore, all tests carry the risk of a false positive result in which a harmless abnormality is incorrectly diagnosed as being a blood clot. In these cases, women can be given unnecessary treatment to thin the blood, which can cause serious bleeding in a small number of people. The number of women that are tested for PE and then found not to have it is quite high, and shows how keen health professionals are to not miss this potentially fatal condition. However, these tests could be causing harm to perfectly healthy expectant mothers and their babies. Clinical prediction rules, in which researchers try to work out which combination of symptoms and other medical findings are most likely to be caused by a particular medical condition, have been used to identify which non-pregnant patients that are showing symptoms of PE need further investigation. These, however, have not been properly tested in pregnant women. The small number of pregnant women with suspected PE that are then diagnosed with the condition makes it very difficult to do this. We estimate that, for such a study, we would need 6000 women across 50 hospitals over 6 years at a cost of £6million, with no guarantee of a reliable result. We are therefore trying a different approach, testing ways of selecting pregnant and postpartum women (women who have just given birth) that may have PE for further investigation. Our study will also test whether there are enough eligible women willing to take part in the research to make further study worthwhile.

Who can participate?
1. Pregnant and postpartum women with diagnosed or suspected PE from all UK hospitals.
2. Pregnant and postpartum women with suspected PE or diagnosed deep vein thrombosis (a blood clot in the vein which may then cause a PE) from 8 hospitals over 18 months

What does the study involve?
Data will be collected over the next 18 months from all UK hospitals from women who either may have the condition, or have actually been diagnosed. Using this data, we are going to test both existing clinical prediction rules, rules that have been improved and new rules to see which correctly predicts which women had PE. We are also collecting blood from pregnant women with deep vein thrombosis to see whether blood tests can accurately identity clots. A mathematical model will be developed, which will weigh up the benefits of diagnosing and treating PE against the risks and the costs involved. This model will then be used to compare different ways of testing for PE and decide which one is best. It will also explore whether the cost of further research is justified given the smaller number of women that have to be tested for PE.

What are the possible benefits and risks of participating?
There are no significant risks or benefits associated with taking part. Some women will be asked to provide a small additional amount of blood when a sample is taken for diagnostic testing.

Where is the study run from?
Sheffield Teaching Hospital NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?
October 2014 to March 2015

Who is funding the study?
National Institute for Health Research Health Technology Assessment Programme (UK)

Who is the main contact?
Prof Steve Goodacre

Trial website

Contact information



Primary contact

Prof Steve Goodacre


Contact details

Regent Court
Regent Street
S1 4DA
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number

HTA 13/21/01

Study information

Scientific title

Diagnosis of pulmonary embolism in pregnancy: a case-control study, biomarker study and decision-analysis modelling of effectiveness, cost-effectiveness and value of information



Study hypothesis

This study aims to:
1. Estimate the diagnostic accuracy, effectiveness and cost-effectiveness of strategies (including clinical prediction rules) for selecting pregnant or postpartum women with suspected PE for imaging
2. Determine the feasibility and value of information of further prospective research

More details can be found at
Protocol can be found at

Ethics approval

NRES Committee London - Brent, 10/10/2014, REC ref: 14/LO/1695

Study design

Case-control study, biomarker study and decision-analysis modelling of effectiveness, cost-effectiveness and value of information

Primary study design


Secondary study design

Case-control study

Trial setting


Trial type


Patient information sheet

Not provided at time of registration


Pulmonary embolism in pregnancy


The study will be testing clinical predictors and biomarkers for PE, and diagnostic strategies (including clinical prediction rules) used to select pregnant or postpartum women for imaging. Data will be collected in hospital up to the point at which women have diagnostic imaging and then by hospital record review and email/telephone/mail contact at 30 days.

Intervention type



Not Applicable

Drug names

Primary outcome measure

1. Pulmonary embolism (PE)
2. Cost-effectiveness
The outcome for diagnostic accuracy (case-control) study will be diagnosis of PE based on diagnostic imaging and any adverse events up to 30 days. The outcome for the cost-effectiveness analysis will be life-time quality-adjusted life years (QALYs), estimated by decision analysis modelling.

Secondary outcome measures


Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Pregnant and postpartum women with diagnosed PE from all UK hospitals over 18 months
2. Pregnant and postpartum women with suspected PE or diagnosed DVT from 8 hospitals over 18 months

Participant type


Age group




Target number of participants

150 women with diagnosed PE, 250 with suspected PE and 20 with diagnosed DVT

Participant exclusion criteria

1. Women who did not present with suspected PE
2. Women who are unable to consent, requiring resuscitation or with an existing diagnosis of PE

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Regent Court
S1 4DA
United Kingdom

Sponsor information


Sheffield Teaching Hospital NHS Foundation Trust (UK)

Sponsor details

c/o Erica Wallis
S10 2SE
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

Health Technology Assessment Programme

Alternative name(s)

NIHR Health Technology Assessment Programme, HTA

Funding Body Type

government organisation

Funding Body Subtype

Federal/National Government


United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

IPD sharing statement
The data sharing plans for the current study are unknown and will be made available at a later date.

Intention to publish date

Participant level data

To be made available at a later date

Basic results (scientific)

See additional file ISRCTN21245595_BasicResults_21Jun18.pdf

Publication list

1. 2018 results in
2. 2018 results in
3. 2018 results in

Publication citations

Additional files

Editorial Notes

05/09/2018: Publication reference added. 21/06/2018: The basic results of this trial have been uploaded as an additional file. 15/06/2018: Publication references added. 12/11/2014: The overall trial end date was changed from 31/03/2015 to 31/03/2017.